BioMarin Announces Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BioMarin Pharma (BMRN) Q2 Revenues Miss; Reaffirms FY Revs
August 1, 2019 4:59 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q2 GAAP EPS of ($0.21), which may not compare to the analyst estimate of ($0.10). Revenue for the quarter came in at $387.8 million versus the consensus estimate of $415.04 million.
GUIDANCE:
BioMarin Pharma reafffirms FY2019 revenue of... More
